CN106723087A - A kind of tablet containing kelp dietary fiber and preparation method thereof - Google Patents
A kind of tablet containing kelp dietary fiber and preparation method thereof Download PDFInfo
- Publication number
- CN106723087A CN106723087A CN201611021537.1A CN201611021537A CN106723087A CN 106723087 A CN106723087 A CN 106723087A CN 201611021537 A CN201611021537 A CN 201611021537A CN 106723087 A CN106723087 A CN 106723087A
- Authority
- CN
- China
- Prior art keywords
- dietary fiber
- phosphatide
- kelp dietary
- oligosaccharide
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013325 dietary fiber Nutrition 0.000 title claims abstract description 196
- 241000512259 Ascophyllum nodosum Species 0.000 title claims abstract description 170
- 238000002360 preparation method Methods 0.000 title claims abstract description 13
- 239000000314 lubricant Substances 0.000 claims abstract description 59
- 239000000463 material Substances 0.000 claims abstract description 43
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 38
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 34
- 210000004369 blood Anatomy 0.000 claims abstract description 33
- 239000008280 blood Substances 0.000 claims abstract description 32
- 206010010774 Constipation Diseases 0.000 claims abstract description 26
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 19
- 235000013402 health food Nutrition 0.000 claims abstract description 9
- 239000003826 tablet Substances 0.000 claims description 112
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical group [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 102
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 75
- 235000019359 magnesium stearate Nutrition 0.000 claims description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 50
- 235000020985 whole grains Nutrition 0.000 claims description 44
- 235000003599 food sweetener Nutrition 0.000 claims description 42
- 239000003765 sweetening agent Substances 0.000 claims description 42
- 238000007605 air drying Methods 0.000 claims description 39
- 239000000377 silicon dioxide Substances 0.000 claims description 38
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 37
- 235000010357 aspartame Nutrition 0.000 claims description 30
- 108010011485 Aspartame Proteins 0.000 claims description 28
- 239000000605 aspartame Substances 0.000 claims description 28
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical group OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 28
- 229960003438 aspartame Drugs 0.000 claims description 28
- 239000000945 filler Substances 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 26
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 23
- 229930195725 Mannitol Natural products 0.000 claims description 23
- 239000000594 mannitol Substances 0.000 claims description 23
- 235000010355 mannitol Nutrition 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 21
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 claims description 17
- 229940083466 soybean lecithin Drugs 0.000 claims description 17
- 239000008103 glucose Substances 0.000 claims description 15
- 235000012054 meals Nutrition 0.000 claims description 15
- 206010020772 Hypertension Diseases 0.000 claims description 13
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 13
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 13
- 239000000811 xylitol Substances 0.000 claims description 13
- 235000010447 xylitol Nutrition 0.000 claims description 13
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 13
- 229960002675 xylitol Drugs 0.000 claims description 13
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 12
- 241000196324 Embryophyta Species 0.000 claims description 11
- 241001465754 Metazoa Species 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000007910 chewable tablet Substances 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 8
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 claims description 8
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 claims description 8
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical group CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 7
- 244000068988 Glycine max Species 0.000 claims description 7
- 235000010469 Glycine max Nutrition 0.000 claims description 7
- 208000008589 Obesity Diseases 0.000 claims description 7
- -1 glycosyl sphingolipid Chemical class 0.000 claims description 7
- 210000004185 liver Anatomy 0.000 claims description 7
- 235000020824 obesity Nutrition 0.000 claims description 7
- 235000010413 sodium alginate Nutrition 0.000 claims description 7
- 239000000661 sodium alginate Substances 0.000 claims description 7
- 229940005550 sodium alginate Drugs 0.000 claims description 7
- 239000007888 film coating Substances 0.000 claims description 6
- 238000009501 film coating Methods 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 5
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical group CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 claims description 5
- NUFKRGBSZPCGQB-FLBSXDLDSA-N (3s)-3-amino-4-oxo-4-[[(2r)-1-oxo-1-[(2,2,4,4-tetramethylthietan-3-yl)amino]propan-2-yl]amino]butanoic acid;pentahydrate Chemical compound O.O.O.O.O.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C.OC(=O)C[C@H](N)C(=O)N[C@H](C)C(=O)NC1C(C)(C)SC1(C)C NUFKRGBSZPCGQB-FLBSXDLDSA-N 0.000 claims description 5
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 5
- 239000004377 Alitame Substances 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 239000004384 Neotame Substances 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 5
- 229930006000 Sucrose Natural products 0.000 claims description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 5
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 5
- 229960004998 acesulfame potassium Drugs 0.000 claims description 5
- 239000000619 acesulfame-K Substances 0.000 claims description 5
- 235000019409 alitame Nutrition 0.000 claims description 5
- 108010009985 alitame Proteins 0.000 claims description 5
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 235000019412 neotame Nutrition 0.000 claims description 5
- HLIAVLHNDJUHFG-HOTGVXAUSA-N neotame Chemical compound CC(C)(C)CCN[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 HLIAVLHNDJUHFG-HOTGVXAUSA-N 0.000 claims description 5
- 108010070257 neotame Proteins 0.000 claims description 5
- 239000002994 raw material Substances 0.000 claims description 5
- 229940085605 saccharin sodium Drugs 0.000 claims description 5
- 229940013618 stevioside Drugs 0.000 claims description 5
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 5
- 235000019202 steviosides Nutrition 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- 239000005720 sucrose Substances 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxane-3,4,5-triol Chemical compound OCC1OC(OC2C(O)C(O)C(O)OC2CO)C(O)C(O)C1O GUBGYTABKSRVRQ-UHFFFAOYSA-N 0.000 claims description 4
- QIGJYVCQYDKYDW-UHFFFAOYSA-N 3-O-alpha-D-mannopyranosyl-D-mannopyranose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(CO)OC(O)C1O QIGJYVCQYDKYDW-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 4
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 claims description 4
- 229920001353 Dextrin Polymers 0.000 claims description 4
- 239000004375 Dextrin Substances 0.000 claims description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 229920000881 Modified starch Polymers 0.000 claims description 4
- 235000021314 Palmitic acid Nutrition 0.000 claims description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 239000001361 adipic acid Substances 0.000 claims description 4
- 235000011037 adipic acid Nutrition 0.000 claims description 4
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 4
- 239000008116 calcium stearate Substances 0.000 claims description 4
- 235000013539 calcium stearate Nutrition 0.000 claims description 4
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 claims description 4
- 235000019425 dextrin Nutrition 0.000 claims description 4
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 claims description 4
- 239000001530 fumaric acid Substances 0.000 claims description 4
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 4
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 4
- 239000008101 lactose Substances 0.000 claims description 4
- 229960003511 macrogol Drugs 0.000 claims description 4
- 239000000845 maltitol Substances 0.000 claims description 4
- 235000010449 maltitol Nutrition 0.000 claims description 4
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 4
- 229940035436 maltitol Drugs 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 claims description 4
- TZBAVQKIEKDGFH-UHFFFAOYSA-N n-[2-(diethylamino)ethyl]-1-benzothiophene-2-carboxamide;hydrochloride Chemical compound [Cl-].C1=CC=C2SC(C(=O)NCC[NH+](CC)CC)=CC2=C1 TZBAVQKIEKDGFH-UHFFFAOYSA-N 0.000 claims description 4
- QIGJYVCQYDKYDW-NSYYTRPSSA-N nigerose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](CO)OC(O)[C@@H]1O QIGJYVCQYDKYDW-NSYYTRPSSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000011574 phosphorus Substances 0.000 claims description 4
- 229910052698 phosphorus Inorganic materials 0.000 claims description 4
- 229940114930 potassium stearate Drugs 0.000 claims description 4
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 claims description 4
- 229960001462 sodium cyclamate Drugs 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 102000002322 Egg Proteins Human genes 0.000 claims description 3
- 108010000912 Egg Proteins Proteins 0.000 claims description 3
- 229930091371 Fructose Natural products 0.000 claims description 3
- 239000005715 Fructose Substances 0.000 claims description 3
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 3
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 3
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 claims description 3
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 3
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- 210000004556 brain Anatomy 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 210000000232 gallbladder Anatomy 0.000 claims description 3
- 210000002216 heart Anatomy 0.000 claims description 3
- 210000003734 kidney Anatomy 0.000 claims description 3
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 claims description 3
- 229960000511 lactulose Drugs 0.000 claims description 3
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 claims description 3
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 3
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 3
- 229960001855 mannitol Drugs 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- IQXJCCZJOIKIAD-UHFFFAOYSA-N 1-(2-methoxyethoxy)hexadecane Chemical compound CCCCCCCCCCCCCCCCOCCOC IQXJCCZJOIKIAD-UHFFFAOYSA-N 0.000 claims description 2
- LRYZPFWEZHSTHD-HEFFAWAOSA-O 2-[[(e,2s,3r)-2-formamido-3-hydroxyoctadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium Chemical class CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](NC=O)COP(O)(=O)OCC[N+](C)(C)C LRYZPFWEZHSTHD-HEFFAWAOSA-O 0.000 claims description 2
- CFWRDBDJAOHXSH-SECBINFHSA-N 2-azaniumylethyl [(2r)-2,3-diacetyloxypropyl] phosphate Chemical compound CC(=O)OC[C@@H](OC(C)=O)COP(O)(=O)OCCN CFWRDBDJAOHXSH-SECBINFHSA-N 0.000 claims description 2
- 235000017060 Arachis glabrata Nutrition 0.000 claims description 2
- 244000105624 Arachis hypogaea Species 0.000 claims description 2
- 235000010777 Arachis hypogaea Nutrition 0.000 claims description 2
- 235000018262 Arachis monticola Nutrition 0.000 claims description 2
- 240000002791 Brassica napus Species 0.000 claims description 2
- 235000004977 Brassica sinapistrum Nutrition 0.000 claims description 2
- 241000283153 Cetacea Species 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- 241000220324 Pyrus Species 0.000 claims description 2
- 229960000250 adipic acid Drugs 0.000 claims description 2
- 229950009789 cetomacrogol 1000 Drugs 0.000 claims description 2
- 235000012343 cottonseed oil Nutrition 0.000 claims description 2
- GXGAKHNRMVGRPK-UHFFFAOYSA-N dimagnesium;dioxido-bis[[oxido(oxo)silyl]oxy]silane Chemical compound [Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O GXGAKHNRMVGRPK-UHFFFAOYSA-N 0.000 claims description 2
- 229960002598 fumaric acid Drugs 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 239000000391 magnesium silicate Substances 0.000 claims description 2
- 229940099273 magnesium trisilicate Drugs 0.000 claims description 2
- 229910000386 magnesium trisilicate Inorganic materials 0.000 claims description 2
- 235000019793 magnesium trisilicate Nutrition 0.000 claims description 2
- XRRONFCBYFZWTM-UHFFFAOYSA-N octadecanoic acid;sodium Chemical compound [Na].CCCCCCCCCCCCCCCCCC(O)=O XRRONFCBYFZWTM-UHFFFAOYSA-N 0.000 claims description 2
- 210000004681 ovum Anatomy 0.000 claims description 2
- 229940098695 palmitic acid Drugs 0.000 claims description 2
- 239000012188 paraffin wax Substances 0.000 claims description 2
- 235000020232 peanut Nutrition 0.000 claims description 2
- 235000021017 pears Nutrition 0.000 claims description 2
- 238000000746 purification Methods 0.000 claims description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 2
- 239000004299 sodium benzoate Substances 0.000 claims description 2
- 235000010234 sodium benzoate Nutrition 0.000 claims description 2
- 239000011122 softwood Substances 0.000 claims description 2
- 229960004274 stearic acid Drugs 0.000 claims description 2
- 235000020238 sunflower seed Nutrition 0.000 claims description 2
- 239000000052 vinegar Substances 0.000 claims description 2
- 235000021419 vinegar Nutrition 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 229920001221 xylan Polymers 0.000 claims description 2
- 150000004823 xylans Chemical class 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 claims 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- HGPXWXLYXNVULB-UHFFFAOYSA-M lithium stearate Chemical compound [Li+].CCCCCCCCCCCCCCCCCC([O-])=O HGPXWXLYXNVULB-UHFFFAOYSA-M 0.000 claims 1
- 230000001050 lubricating effect Effects 0.000 claims 1
- DKXULEFCEORBJK-UHFFFAOYSA-N magnesium;octadecanoic acid Chemical compound [Mg].CCCCCCCCCCCCCCCCCC(O)=O DKXULEFCEORBJK-UHFFFAOYSA-N 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 229910052938 sodium sulfate Inorganic materials 0.000 claims 1
- 235000011152 sodium sulphate Nutrition 0.000 claims 1
- 239000011701 zinc Substances 0.000 claims 1
- 229910052725 zinc Inorganic materials 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 230000009467 reduction Effects 0.000 abstract description 7
- 229910001385 heavy metal Inorganic materials 0.000 abstract description 3
- 230000003712 anti-aging effect Effects 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract description 2
- 230000007717 exclusion Effects 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 150000003904 phospholipids Chemical class 0.000 abstract description 2
- 230000001151 other effect Effects 0.000 abstract 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 50
- 238000000034 method Methods 0.000 description 44
- 230000033228 biological regulation Effects 0.000 description 42
- 230000008569 process Effects 0.000 description 40
- 239000012634 fragment Substances 0.000 description 39
- 239000008213 purified water Substances 0.000 description 39
- 239000000047 product Substances 0.000 description 38
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 34
- 239000003925 fat Substances 0.000 description 33
- 235000019197 fats Nutrition 0.000 description 33
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 27
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 19
- 201000010099 disease Diseases 0.000 description 17
- 235000012000 cholesterol Nutrition 0.000 description 10
- 241000894006 Bacteria Species 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 239000000835 fiber Substances 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 8
- 230000013872 defecation Effects 0.000 description 8
- 230000036541 health Effects 0.000 description 8
- 239000011777 magnesium Substances 0.000 description 8
- 229910052749 magnesium Inorganic materials 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 238000010521 absorption reaction Methods 0.000 description 7
- 235000014633 carbohydrates Nutrition 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 7
- 238000005469 granulation Methods 0.000 description 7
- 230000003179 granulation Effects 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Substances N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 7
- 230000000968 intestinal effect Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 235000015097 nutrients Nutrition 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 150000001720 carbohydrates Chemical class 0.000 description 6
- 235000013339 cereals Nutrition 0.000 description 6
- 239000007941 film coated tablet Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 238000012935 Averaging Methods 0.000 description 4
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 4
- 208000017170 Lipid metabolism disease Diseases 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 230000000378 dietary effect Effects 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 230000007661 gastrointestinal function Effects 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- 238000005461 lubrication Methods 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 230000008855 peristalsis Effects 0.000 description 4
- 239000007940 sugar coated tablet Substances 0.000 description 4
- 235000019605 sweet taste sensations Nutrition 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 3
- PVXPPJIGRGXGCY-TZLCEDOOSA-N 6-O-alpha-D-glucopyranosyl-D-fructofuranose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 PVXPPJIGRGXGCY-TZLCEDOOSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 102000004877 Insulin Human genes 0.000 description 3
- 108090001061 Insulin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 239000003613 bile acid Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 201000005577 familial hyperlipidemia Diseases 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 201000001320 Atherosclerosis Diseases 0.000 description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 description 2
- 239000004380 Cholic acid Substances 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 2
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 235000019416 cholic acid Nutrition 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 229960002471 cholic acid Drugs 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 208000016097 disease of metabolism Diseases 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000005802 health problem Effects 0.000 description 2
- 230000036737 immune function Effects 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 229920005610 lignin Polymers 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 2
- 229910052753 mercury Inorganic materials 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000003094 microcapsule Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000000630 rising effect Effects 0.000 description 2
- 229940114926 stearate Drugs 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- LGQKSQQRKHFMLI-SJYYZXOBSA-N (2s,3r,4s,5r)-2-[(3r,4r,5r,6r)-4,5,6-trihydroxyoxan-3-yl]oxyoxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)OC1 LGQKSQQRKHFMLI-SJYYZXOBSA-N 0.000 description 1
- JCSJTDYCNQHPRJ-UHFFFAOYSA-N 20-hydroxyecdysone 2,3-acetonide Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(OC2C(C(O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-UHFFFAOYSA-N 0.000 description 1
- LGQKSQQRKHFMLI-UHFFFAOYSA-N 4-O-beta-D-xylopyranosyl-beta-D-xylopyranose Natural products OC1C(O)C(O)COC1OC1C(O)C(O)C(O)OC1 LGQKSQQRKHFMLI-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108010004103 Chylomicrons Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- SQNRKWHRVIAKLP-UHFFFAOYSA-N D-xylobiose Natural products O=CC(O)C(O)C(CO)OC1OCC(O)C(O)C1O SQNRKWHRVIAKLP-UHFFFAOYSA-N 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000014540 Functional gastrointestinal disease Diseases 0.000 description 1
- 241000246500 Gentianella aspera Species 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 241000167880 Hirundinidae Species 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- 102100022365 NAD(P)H dehydrogenase [quinone] 1 Human genes 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 239000004280 Sodium formate Substances 0.000 description 1
- 241000209140 Triticum Species 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 108010066657 azoreductase Proteins 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- JCSJTDYCNQHPRJ-FDVJSPBESA-N beta-D-Xylp-(1->4)-beta-D-Xylp-(1->4)-D-Xylp Chemical compound O[C@@H]1[C@@H](O)[C@H](O)CO[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)C(O)OC2)O)OC1 JCSJTDYCNQHPRJ-FDVJSPBESA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000035850 clinical syndrome Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- FRKBLBQTSTUKOV-UHFFFAOYSA-N diphosphatidyl glycerol Natural products OP(O)(=O)OCC(OP(O)(O)=O)COP(O)(O)=O FRKBLBQTSTUKOV-UHFFFAOYSA-N 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000007919 dispersible tablet Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000012055 fruits and vegetables Nutrition 0.000 description 1
- 208000020694 gallbladder disease Diseases 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 238000007542 hardness measurement Methods 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000003516 hyperlipidaemic effect Effects 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000007235 immunity generation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- FSWZDJUNHJMBSQ-UHFFFAOYSA-N lithium;octadecanoic acid Chemical compound [Li].CCCCCCCCCCCCCCCCCC(O)=O FSWZDJUNHJMBSQ-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 238000012946 outsourcing Methods 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- HLBBKKJFGFRGMU-UHFFFAOYSA-M sodium formate Chemical compound [Na+].[O-]C=O HLBBKKJFGFRGMU-UHFFFAOYSA-M 0.000 description 1
- 235000019254 sodium formate Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- ABKNGTPZXRUSOI-UHFFFAOYSA-N xylotriose Natural products OCC(OC1OCC(OC2OCC(O)C(O)C2O)C(O)C1O)C(O)C(O)C=O ABKNGTPZXRUSOI-UHFFFAOYSA-N 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention relates to a kind of tablet containing kelp dietary fiber and preparation method thereof, belong to health food and its manufacture field.The disclosed tablet containing kelp dietary fiber, its active component is kelp dietary fiber, oligosaccharide, phosphatide, and auxiliary material is pharmaceutically acceptable tablet preparation auxiliary material, and the auxiliary material comprises at least lubricant.The present invention is by kelp dietary fiber, oligosaccharide, together, three plays synergy to phospholipid combination, with fat-reducing, treatment constipation, diabetes, reduction high fat of blood, anti-aging, antitumor, the internal heavy metal of exclusion and other effects are treated, especially to treatment anti-constipation effect clearly.
Description
Technical field
The present invention relates to a kind of tablet of kelp dietary fiber and preparation method thereof, belong to health food and its processing neck
Domain.
Background technology
With the development of social economy, the rhythm of life of people is accelerated, operating pressure increase, the life of long-term excess load
And operating pressure, the people for causing the world 70% is with different degrees of enterogastric diseases.Constipation is clinically most commonly seen
Functional gastrointestinal disease, is mainly shown as defecation frequency is reduced, excrement amount is reduced, excrement is dry and hard, defecation is laborious etc..Constipation is not
Only it is a kind of common health problem, is also many fatal rate diseases, such as acute cardiovascular and cerebrovascular disease, dementia, colon cancer is lured
Hair factor, illness rate is up to 27%.In recent years, with the change of people's dietary structure and the shadow of psychiatric and social factor
Ring, the constipation incidence of disease is also in increased trend, has had a strong impact on the quality of life of people, and its cause of disease is complicated, be difficult to control
Treat, a kind of public disease of easily recurrence, factor already the turns into puzzlement society such as treatment phase is permanent and side effect is big.
Obesity is a kind of chronic metabolic disease caused by many factors, with the volume and cell of body fat cell
The percentage that number increases cause body fat percentage of liveweight increases and with the characteristics of some local excessive deposition fat extremely.Recent two decades come,
With developing rapidly for China's economy, living standards of the people are improved constantly, and life modernization diet structure changes and muscle power
Active day is decrescence few, and fat phenomenon is more and more universal, and at present, obesity instead of as caused by malnutritive and infection
Disease, suddenly becomes the primary killers of harm human health.It is known it is fat with diabetes, angiocardiopathy, some tumours and
The diseases such as sleep-disordered breathing have obvious dependency relation, and fat cohesive disease includes：Coronary heart disease, hypertension and apoplexy, some
Cancer, adult-onset diabetes, gallbladder disease, osteoarthritis and gout, dyslipidemia, Pulmonary Diseases, including sleep
Apnea, obesity is the kinds cancers such as hypertension, diabetes, dyslipidemia, coronary heart disease, myocardial infarction, palsy, breast cancer hair
Raw Major Risk Factors, unhealthful the fifth-largest hazards are regarded as by the World Health Organization.
Hypertension (hypertension) refers to be increased as main with systemic arterial blood pressure (systolic pressure and/or diastolic pressure)
Feature (systolic pressure >=140 millimetres of mercury, diastolic pressure >=90 millimetres of mercury), can be with the function of the organs such as the heart, brain, kidney or device matter
Property infringement clinical syndrome.Hypertension is most common chronic disease, is also the topmost hazards of cardiovascular and cerebrovascular diseases.Tentatively
There is hyperpietic 2.66 hundred million in estimation China in 2012.Research both at home and abroad confirms that the blood pressure level for reducing hyperpietic can
Cerebral apoplexy and 15%~30% myocardial infarction for reducing 40%~50% are dangerous.Therefore, control hypertension is that cardiovascular disease is prevented
The point of penetration controlled.
Diabetes are to increase the metabolic disease being characterized with chronic blood glucose levels, by insulin secretion and (or) work
Caused with defect, with the progress of the state of an illness, to all Multisystem damages of human body, be greatly reduced minimal invasive treatment's level.United according to WHO
Meter, global diabetic is more than 1.7 hundred million within 2000, it is contemplated that the year two thousand thirty will be more than 3.6 hundred million.China's diabetes prevalence is in fast
Fast increase trend.Newest epidemiology survey shows that Chinese Adult diabetes prevalence had reached 11.6% in 2010.Glycosuria
The rising of the sick incidence of disease, increased individual, family, the burden of society.There is investigation to show, China city, small towns and rich rural area
In the crowd of more than 20 years old, diabetes prevalence up to 9.7%, also 15.5% people's impaired glucose regulation in addition.Diabetes
Capilary and macrovascular complications can cause to disable, lethal dangerous and huge financial burden, and diabetes have become influence and occupy
The subject matter of people's health.
Hyperlipidemia is defined as blood fat disorder or dyslipidemia, refers to the concentration level of blood in human body in fat eliminating matter beyond just
Normal scope, including serum total cholesterol (TC) level is raised.Serum levels of triglyceride (TG) level is raised.Serum high-density fat fat egg
White cholesterol (HDL-C) different attenuating of level.It is one of Major Risk Factors of cardiovascular and cerebrovascular disease.Hyperlipemia is old in being common in
Year people, but change and the rising of drinking amount with dietary structure, young people its illness rate are also increasing year by year.A large amount of epidemic diseases
Learn investigation and research shows that hyperlipemia is to cause various diseases such as atherosclerosis (AS), coronary heart disease, diabetes
Hazards.
For above-mentioned various health and inferior health problems, in addition to traditional therapeutic scheme, nutrition scholarship and moral conduct in recent years
Industry is attempted providing some features, health food and health products and many is asked due to above-mentioned caused by eating habit with improving people
Topic.Among this, dietary fiber is a direction for receiving much concern and promoting at present.Dietary fiber (DietaryFiber, DF)
It is the compound mixture of a class polymer, is not by the polysaccharide carbohydrate and the general name of lignin of human consumption.20 generation
The discipline sixties and its later many research find that edible high fiber food advantageously reduces the diseases such as diabetes, hyperlipidemia
The incidence of disease.Thus arouse interest of the people to dietary fiber, and start systematic research.The research of nutrition and related science
It was found that dietary fiber has a considerable physiological action, and the 7th class nutrient and traditional is regarded as by nutrition educational circles supplement
Six class nutrients --- protein, fat, carbohydrate, vitamin, mineral matter and water are arranged side by side.Although dietary fiber is not by people
Body digestive ferment is decomposed and absorbed, but maintains human body health, it is impossible to a kind of nutrient replaced by other materials.Largely
It turns out that, dietary fiber can make human body intestinal canal keep normal creepage of gastrointestinal functions, with protein, fat, using carbohydrate, dimension
Digesting and assimilating for raw plain, mineral matter is relevant, in appropriate amount complementary diets fiber, can expand the food in enteron aisle and soften, and promotes intestines
Road is wriggled, and so as to accelerate defecation speed, is prevented constipation and is reduced the risk of intestinal cancer.Other dietary fiber is to fat, cardiovascular
The illness such as disease, diabetes, heart disease, self immune system disorder have mitigation.
Dietary fiber is widely present in cereal, beans, water fruits and vegetables and marine algae, the meals extracted by different material
Food fiber, its component has larger difference, and its physicochemical property and physiological function have the difference of highly significant.Among this, sea
Band causes the extensive concern of nutrition educational circles in recent years as a kind of ocean crops rich in multiple nutritional components.
CN101317666A discloses a kind of high-efficiency composite food cellulose, by insoluble diedairy fiber, aqueous soluble dietary
Fiber, vitamin C, lactic acid bacteria powder etc. are prepared as capsule, electuary, but the consumption of dietary fiber is too high in this scenario, and
Lack dietary fiber compounding composition so that its mouthfeel is poor, and local flavor is poor, is difficult to be received by consumer.CN102077939 is public
A kind of sea dietary has been opened, with food-borne marine oligopeptide as primary raw material, marine bioactivity polysaccharide has been added, then be aided with
Seawood meal, nutrient amino acids, oligosaccharide, nutrient, vitamin and mineral matter are mixed with and form.The product form is complicated, raw
Produce and cost of material is higher, it is difficult to marketing.CN103202469 discloses a kind of microcapsules, is with egg yolk lecithin
Core, sodium alginate, shitosan is used as wall material.Such microcapsules are very low to egg yolk lecithin, the sodium alginate amount of containing, it is impossible to
Give full play to the activity of the two.
The content of the invention
In the present invention, involved term is following concept：
Alleged tablet means that material medicine or the circular or special-shaped sheet being made with suitable auxiliary material are consolidated in the present invention
Body preparation, as understood by those skilled in the art, its common dosage forms includes ordinary tablet, lozenge, sublingual tablet, mouth paster, nozzle
Chew piece, dispersible tablet, fuse, effervescent tablet, sustained release tablets, controlled release tablet, enteric coatel tablets, oral disintegrating tablet etc..
In the present invention alleged active component refer to human body take absorption in contribute to improve function of human body, overcome people
The composition of body physiological disorders.
In the present invention alleged auxiliary material refer to excipient used in the preparation process such as medicine, health products, food and
Additives, pharmaceutically acceptable refers to be had confirmed in existing pharmaceutical applications to patient's relative nontoxic, harmless.
The invention discloses a kind of tablet containing kelp dietary fiber, its active component be kelp dietary fiber, oligosaccharide,
Phosphatide, auxiliary material is pharmaceutically acceptable tablet preparation auxiliary material, and the auxiliary material comprises at least lubricant.
For the ease of taking, it is easy to absorb, the formulation of preferably above-mentioned alleged tablet is chewable tablets.
Applicant passes through the lot of experiments composition consumption of mentioned component, it is preferred that in terms of mass fraction, sea-tangle meals
Eat fiber 30-70, oligosaccharide 10-40, phosphatidase 1 0-40, the lubricant 0.2-6 in auxiliary material.
In above-mentioned, alleged auxiliary material is referred in tablet of the invention including at least lubricant, at least uses lubrication
Agent this auxiliary material.In addition, the need for according to formulation, production etc., it is also possible to use other types of auxiliary material.
Accordingly, present invention also offers the preparation method of above-mentioned tablet, comprise the following steps：
A), to cross 60-200 mesh sieves standby for kelp dietary fiber；
B) kelp dietary fiber, oligosaccharide, phosphatide, is weighed to be well mixed；
C), add water softwood processed, is pelletized with 14-30 mesh sieves, is put into forced air drying 0.5h-4h in 40 DEG C of -70 DEG C of baking ovens；
D), take out and use 14-30 mesh sieve whole grains, always mixed after adding lubricant；
E), piece weight piece according to the rules.
When auxiliary material used also includes other the auxiliary material types in addition to lubricant, its outside lubricant is added in step b)
Its auxiliary material.
In above step, a) kelp dietary fiber crosses 60-200 mesh sieves, it is therefore an objective to makes the outward appearance of product good, and has
Excellent property, granularity is the smaller the better in theory, but granularity is small, Grin-ding energ7 increase, and mobility is deteriorated, therefore 60-200 mesh
, properties can reach requirement.Wherein preferably 100 mesh.
In above step, c) to be pelletized in step and can reach requirement from 14-30 mesh sieves, wherein it is preferred that 20 mesh sieves are whole
Grain, drying temperature is selected from 40 DEG C -70 DEG C.Wherein temperature is less than 40 DEG C, and drying efficiency is too low, higher than under 70 DEG C of material stability
Drop, preferably 45 DEG C -55 DEG C.Drying time determines that the time is between 0.5h-4h according to factors such as drying temperature, the thin and thicks of material.
Wherein if drying temperature it is high, if material is thin drying time it is short, if drying temperature it is low, if material is thick drying time it is long.This area skill
Art personnel can determine corresponding drying time according to dry temperature.
In above step, whole grain d) is carried out from 14-30 mesh sieves in step, the sieve mesh selected when typically according to granulation is entered
Row selection, granulation is sieved with much mesh numbers, is also sieved with much mesh numbers in whole grain.
In above step, e) compressing tablet in step, according to the piece weight or the measure knot of design piece weight and granule content of design
Fruit calculates and answers compressing tablet weight, carries out compressing tablet, and piece controls to meet States Pharmacopoeia specifications again.Those skilled in the art can realize.
To based on formulation derived from tablet, being such as surrounded by the tablet of film-coating or sugar-coat, also comprising film coating or bag sugar
The step of clothing.Wherein can bag gastric solubility film-coating or enteric film clothing or sugar-coat, the material used and technique sheet of coating
Product can be realized without particular/special requirement, those skilled in the art.
Finally, present invention also offers the purposes of the kelp dietary fiber tablet, including but not limited to fat-reducing is being prepared
Application in terms of medicine or health food, the application in terms for the treatment of constipation medicine or health food is prepared is preparing treatment glycosuria
Application in terms of medicine or health food, the application in terms for the treatment of high blood cholesterol drug or health food is prepared is anti-preparing
Application in terms of hypertension drug or health food.
In following, in order to present disclosure is better described, applicant enters to composition used by technical solution of the present invention
Go and elaborated, so that those skilled in the art more fully understand the present invention.
In kelp dietary fiber tablet of the present invention, kelp dietary fiber is selected from water-soluble kelp dietary fiber, water-insoluble
One kind or its mixture in kelp dietary fiber, preferably water-soluble kelp dietary fiber and water-insoluble kelp dietary fiber
Mixture.
Wherein, water-soluble kelp dietary fiber used preferably uses sodium alginate.
In tablet of the invention, oligosaccharide be selected from xylo-oligosaccharide, oligoisomaltose, FOS, galactooligosaccharide,
Soyabean oligosaccharides, raffinose-oligosaccharide, inulooligosaccharide, oligomeric dragon gallbladder sugar, oligomeric isomaltulose, oligomeric nigerose, oligomeric idol
One or more in sugar, arabinooligosaccharides, lactulose, trehalose, stachyose, shitosan, chitosan is closed, it is preferably oligomeric
Xylose.
In tablet of the invention, phosphatide is selected from one kind in phosphatide, the phosphatide of animal origin of plant origin or it is mixed
Compound, or plant origin phosphatide, the separated single component phosphatide after purification of phosphatide of animal origin；Wherein plant origin
It with the vegetable oil materials such as soybean, cottonseed, rapeseed, shelled peanut, sunflower seeds or its processing byproduct is primary raw material through carrying that phosphatide is
Phosphatide obtained by refining is taken, Ministry of Health of the People's Republic of China's issue is preferably conformed to《National Standard of the People's Republic of China-
GB28401-2012》Phosphatide；The phosphatide of wherein animal origin refers to groups such as the ovum of animal, brain, liver, kidney, heart, lungs
Be woven to raw material it is extracted it is refined obtained by phosphatide；Single component phosphatide after wherein isolating and purifying is selected from lecithin, cephalin, flesh
In alcohol phosphatide, serinephosphatide, phosphatidyl glycerol, diphosphatidylglycerol, plasmalogen, lysophosphatide, sphingomyelins, glycosyl sphingolipid
It is a kind of.
Wherein, the preferred soybean lecithin of the phosphatide of the plant origin, the preferred egg yolk lecithin of phosphatide of the animal origin.
In tablet of the invention, lubricant is selected from magnesium stearate, calcium stearate, zinc stearate, stearic acid sodium, stearic acid
Lithium, potassium stearate, stearic acid, palmitic acid, magnesium trisilicate, synthetic wax, hard paraffin, hydrogenated vegetable oil, whale vinegar alcohol, monostearate are sweet
Grease, silicified microcrystalline cellulose, silica, talcum powder, Sodium Benzoate, enuatrol, sldium lauryl sulfate, laruyl alcohol sulfuric acid
One kind in magnesium, adipic acid, fumaric acid, cetomacrogol 1000, Macrogol 4000, Macrogol 6000, sodium chloride, leucine
Or various, preferably magnesium stearate, silica or the mixture of the two.
It should be readily apparent to one skilled in the art that for edible convenience, it is also an option that add other it is various required for
Auxiliary material.
To increase the mouthfeel of this product, sweetener is also included in the auxiliary material of Tablets, described sweetener is selected from Ah Si
Pa Tan (Aspartame), saccharin sodium, Sucralose, sodium cyclamate (honey element), alitame, neotame (N- [N- (3,3- dimethyl
Butyl)-L- α-aspartoyl]-L-phenylalanine 1- methyl esters), acesulfame potassium, stevioside, mannitol, xylitol, sorbierite, fruit
One or more in sugar, glucose, maltose, sucrose.In view of diabetes patient and fat-reducing patient's application, in above-mentioned sweetener
In can preferably increase sweet taste but not increase heat, that is, with sweet taste, without providing energy, the sweet taste of blood sugar level is not changed
Agent, including but not limited to aspartame, saccharin sodium, Sucralose, sodium cyclamate (honey element), alitame, neotame (N- [N- (3,
3- dimethylbutyls)-L- α-aspartoyl]-L-phenylalanine 1- methyl esters), acesulfame potassium, stevioside, mannitol, xylitol,
One or more in sorbierite, maltose.
When auxiliary material selects lubricant and sweetener, in terms of mass fraction, the composition of tablet is kelp dietary fiber 30-
70, oligosaccharide 10-40, phosphatidase 1 0-40, lubricant 0.2-6, sweetener 0.1-20.
For make this product have preferably can die mould, and be easy to adjustment sheet weight, filling is also included in the auxiliary material of Tablets
Agent, described filler is selected from mannitol, lactose, microcrystalline cellulose, starch, pregelatinized starch, soluble starch, dextrin, mountain
One or more in pears sugar alcohol, maltitol, oligoisomaltose, preferably mannitol.
When auxiliary material selects lubricant and filler, in terms of mass fraction, the composition of tablet is kelp dietary fiber 30-
70, oligosaccharide 10-40, phosphatidase 1 0-40, lubricant 0.2-6, filler 1-49.
To increase the mouthfeel of this tablet, improve compressibility and be easy to adjustment sheet weight, on the basis of the above, tablet of the invention
Auxiliary material used includes lubricant, sweetener and filler simultaneously, and in terms of mass fraction, the composition of tablet is kelp dietary fiber
30-70, oligosaccharide 10-40, phosphatidase 1 0-40, lubricant 0.2-6, sweetener 0.1-20, filler 1-49.In the composition, institute
Magnesium stearate and silica, wherein magnesium stearate 0.1-3, silica 0.1-3 are preferably used with profit agent.
On the basis of the above, the need for meet market, outward appearance, the need for increasing humidity resistance, increasing stability etc. are improved
Will, tablet of the invention can also be surrounded by film-coating and be made Film coated tablets or be surrounded by sugar-coat and be made sugar coated tablet (Film coated tablets is
Refer to the tablet of the film of outsourcing macromolecular material；It is mainly the tablet that coating material is packed with sugar that sugar coated tablet refers to).
In preferred implementation of the invention, the kelp dietary fiber tablet for being provided is chewable tablets, to be supplied to consumption
The edible way of person's most convenient, promotes medicine dissolving and absorption in vivo, is easy to old man, child, swallows difficult and stomach and intestine work(
The patient of energy difference, reduces burden of the medicine to intestines and stomach.In chewable tablets, the preferred water solubility sea-tangle meals of kelp dietary fiber are fine
The mixture of peacekeeping water-insoluble kelp dietary fiber, the preferred xylo-oligosaccharide of oligosaccharide, the preferred soybean lecithin of phosphatide, lubricant is excellent
Select hard magnesium and silica.
Compared with conventional chewable tablets, the present invention has the fragrance of phosphatide using chewable tablets due to adding phosphatide, mouthfeel because
Phosphatide is added to increase a lot.Phosphatide can promote stomach blood circulation and enterogastric peristalsis simultaneously, help to prevent and improve constipation.
Additionally, using phosphatide this product hardness can not only be reduced, and reduce the friability of this product after hardness and do not rise not only, drop on the contrary
It is low.That is the friability of this product is more preferable.
In the further realization of above-mentioned chewable tablets, sweetener, the preferred aspartame of sweetener are also added with.
Wherein, above-mentioned chewable tablets composition, in terms of mass fraction, kelp dietary fiber 30-70, xylo-oligosaccharide 10-40, phosphorus
Fat 10-40, silica 0.1-3, magnesium stearate 0.1-3, aspartame 0.1-2.Preferably, kelp dietary fiber 49, it is oligomeric
Xylose 24.5, soybean lecithin 24.5, silica 0.5, magnesium stearate 1, aspartame 0.5.
Product of the invention, kelp dietary fiber used be with high-quality sea-tangle as raw material, by alcohol extracting decolouring, deodorant,
Acid carries decalcification magnesium, removal small-molecule substance, and alkalization increases water-soluble kelp dietary fiber, dehydrates the mixed diet being made fine
Dimension.Kelp dietary fiber is made up of water-soluble dietary fiber and water insoluble dietary fiber, and water-soluble dietary fiber is predominantly brown
Mosanom, water insoluble dietary fiber are mainly the constituent of sea-tangle cell membrane, are that one kind is different from land plant cell membrane
Fiber.Water insoluble dietary fiber accounts for 40% in kelp dietary fiber, and water-soluble dietary fiber accounts for 30%, therefore sea-tangle meals are fine
Dimension is uniform to mix by ultramicro grinding, and with very strong retention ability and expansive force, the wheat meals far above terrestrial plant are fine
Dimension, can increase the volume and speed of defecation of human body, mitigate the pressure with urinary system in rectum.Kelp dietary fiber is except having
The water holding expansion of conventional dietary fiber is outer, the absorption of its heavy metal, is digested and assimilated to fat absorption, in alleviation sugar, waits table
Excellent performance is showed.
Product of the invention, oligosaccharide used is the polymer of a small number of monose (2-10) condensation, and it has following spy
Point：Improve micro-ecological environment in human body, be conducive to the propagation of Bifidobacterium and other beneficial bacteriums, intestines are made through metabolism generation organic acid
Interior pH value reduction, suppresses the growth of enteral salmonella and spoilage organisms, adjusts gastrointestinal function, suppresses enteral corrupt substance, changes
Stool, it is anti-to treat constipation, and increase vitamin synthesis, improve immune function of human body；Oligosaccharides used is like water-soluble plant
Fiber, can improve blood lipid metabolism, reduce the content of Blood Cholesterol and triglycerides；Non-insulin is relied on, and will not make blood sugar
Raise, be suitable for hyperglycemia population and diabetes patient；Difficult to digest enzyme hydrolysis by ptyalin and small intestine, caloric value is very low, very
Fat is converted into less, and obesity patient is had no side effect；Matrix is not formed by caries bacteria, also do not condense thalline effect, can prevented
Carious tooth；Suppress the generation of enteral spoilage product, suppress those β relevant with enteral generation carcinogen-grape glucoside acid enzymes and azo
Reductase.
The xylo-oligosaccharide for wherein preferably using be by 2~7 D- xyloses molecules with β-Isosorbide-5-Nitrae-glycosidic bond be formed by connecting it is straight
Arabinose aldehydic acid, glucuronic acid side chain are also contained in chain or side chain low polymerization degree functional sugar, part, wherein with xylobiose and
It is a kind of functional oligomerization carbohydrate prebiotics based on xylotriose.The sweet taste of xylo-oligosaccharide is pure, be similar to sucrose, but its sugariness compared with
Low, xylo-oligosaccharide sweetness ratio sucrose and glucose are low, about the 40% of sucrose.Xylo-oligosaccharide is preferable to the stability of pH and heat,
Even heat also not decomposing substantially in acid condition, and because lack the enzyme system of hydrolysis xylo-oligosaccharide in body gastrointestinal tract
System, therefore xylo-oligosaccharide can pass through stomach and small intestine and not be degraded utilization, and big enteral is directly entered by Bifidobacterium, breast
The beneficial bacteriums such as acidfast bacilli are utilized, and harmful bacteria utilization rate is extremely low or can not utilize, so that beneficial bacterium raised growth is bred.It is low
It, with corncob as raw extract, is most strong to Bifidobacterium proliferation function prebiotics in functional oligose that xylan is.
Can effective regulating intestinal canal microecological balance, and suppress other harmful bacteria growth and breedings, and be difficult to human consumption's enzyme system institute
Decompose.It is a kind of dietary fiber, can increase stool water-holding capacity and stool quantity, and it can make the bacterial fermentation in large intestine and generate
The organic acids such as acetic acid, propionic acid and lactic acid, are acidified enteron aisle, stimulate intestines peristalsis, reach the effect for relaxing bowel.
Product of the invention, phosphatide used is the lipids containing phosphatide root, to activating cell, maintains new old generation
Thank, basic metabolism and hormonal equilibrium are secreted, and strengthen the immunity and regeneration power of human body, can play great effect.Separately
Outward, phosphatide also has promotion fat metabolism, prevents fatty liver, reduce serum cholesterol, improvement blood circulation, prevention of cardiovascular disease
The effect of disease.Other lecithin phospholipid can promote stomach blood circulation and enterogastric peristalsis, help to prevent and improve constipation.
By kelp dietary fiber, oligosaccharide, phospholipid combination together, three plays synergy to the present invention, and they are mutual
Coordinate with constipation of losing weight, treat, treatment diabetes, reduce the work such as high fat of blood, anti-aging, antitumor, the internal heavy metal of exclusion
With.By each different physiological mechanisms particularly under the triple role of kelp dietary fiber, oligosaccharide and phosphatide, with aobvious
The synergy of work, fat-reducing, treatment constipation, treatment diabetes, reduction high fat of blood effect are clearly.
In the present invention, kelp dietary fiber have that quality is loose, network structure substantially, with compared with concrete dynamic modulus and distribution is equal
Even space structure feature, so that the high-expansion of kelp dietary fiber, retentiveness high is far superior to other dietary fibers.This
Invention utilizes the high-expansion of kelp dietary fiber, and retentiveness feature high, retentiveness high can increase the volume and speed of defecation of human body
Degree, and mitigate the pressure in rectum with urinary system.Expansive force and retention ability are higher, and the moisture in feces of discharge is higher,
And volume is big and soft, it is easier by enteron aisle, so that constipation is alleviated.Oligosaccharide in this product can improve Tiny ecosystem in human body
Environment, is conducive to the propagation of Bifidobacterium and other beneficial bacteriums, and intestinal pH is reduced through metabolism generation organic acid, suppresses enteral
Salmonella and the growth of spoilage organisms, adjust gastrointestinal function, suppress enteral corrupt substance, change stool, anti-to treat constipation, and
Increase vitamin synthesis, improve immune function of human body.Phosphatide in this product can promote stomach blood circulation and enterogastric peristalsis, have
Help prevent and improve constipation.This product coordinates this three, and by different mechanism, different aspects treats constipation, therefore three
The mutual synergistic action effect of person is clearly.
In the present invention, kelp dietary fiber can neither be absorbed by pipe intestinal digesting, can not produce energy, sea-tangle meals
Fiber can make human body intestinal canal keep normal creepage of gastrointestinal functions, because kelp dietary fiber has water swellability higher, therefore use
Kelp dietary fiber can produce satiety, reduce food-intake, increase stomach volume, slow down the digesting and emptying speed of stomach, reduce
Uptake of the body to cholesterol；Kelp dietary fiber can also take away unnecessary fat while food-intake is reduced from human body
Fat and energy；Soluble dietary fiber can also form film on gastrointestinal wall in kelp dietary fiber, prevent the absorption of glucose,
Nutrient is hindered to change into heat energy；There is loose structure additionally, due to sea-tangle meals are fine, can absorbing fats and carbohydrate slow down fat
Fat and carbohydrate are absorbed so as to prevent fat and carbohydrate taken in excess, therefore with weight losing function gastral.It is low in this product
, because difficulty is by ptyalin and small intestine digestion enzyme hydrolysis, caloric value is very low, is seldom converted into fat for glycan；Phosphatide can divide in this product
Solution too high blood fat and too high cholesterol, clean blood vessel, make vascular circulation smooth, and phosphatide can also make neutral fat and blood vessel
The cholesterol emulsification of middle deposition is harmless particulate, soluble in water and excrete, while preventing superabundant fats in blood
Tube wall is deposited, and alleviates the pressure of cardiovascular and cerebrovascular wall.Therefore three kinds of components in this product are effective to losing weight, and the mechanism of action is different
Therefore three to share fat-reducing effect obvious.Test example also fully demonstrates function above.
In the present invention, fasting blood glucose level can be significantly reduced in kelp dietary fiber, may is to stimulate the β of remaining thin
Intracrine insulin simultaneously can improve sensitivity of the distal tissues to insulin, reduce the requirement to insulin, be conducive to glycogen
Synthesis, so as to reduce blood sugar level；The upper of level of postprandial blood sugar can significantly be suppressed in this product in kelp dietary fiber
Rise, may be that the soluble kelp dietary fiber in kelp dietary fiber forms a kind of mucous membrane under one's belt, make dietary nutrient
The process of digesting and assimilating slows down such that it is able to suppress the blood glucose rise that exogenous glucose causes.Oligosaccharide in this product is to reducing
Fasting blood-glucose and postprandial blood sugar have certain effect.Dietary fiber has one with oligosaccharide in terms of diabetes blood glucose is reduced
Fixed synergy.The two can play complementation, the result is that the collective effect of the two should be any one more than them
Independent role.
In the present invention, some compositions such as glue can combine cholesterol in dietary fiber, gel can be formed in enteron aisle, reduce
Cholesterol particles are formed, and the lignin that it contains can also be combined with bile acid, bile emulsification are reduced, in interference enteron aisle
The absorption of lipid, reduces and slows down it and absorbed the effect to form chylomicron so that enters internal lipid and reduces, reduces body
Inner cholesterol value, and then influence VLDL (VLDL-C), low-density lipoprotein cholesterol level；Dietary fiber and courage
Acid is combined, and is reduced bile acid and is circulated back in liver and excretes via intestines liver, thus reduces bile acid solution in liver, is increased
Plus in vivo in liver cholesterol metabolism, liver is synthesized cholic acid speed increases, and reduces hepatic cholesterol concentration, in addition cholic acid
The increase of excretion also can reduce the amount that intestinal cholesterol is emulsified absorption, then also just reduce internal cholesterol level.It is oligomeric
Sugar generally has indigestibility, the characteristic that sugariness is low and heat is low, so being not readily converted into metabolism of lipid and cholesterol.For hyperlipemia
Individuality for, the main effects of oligosaccharide is to reduce cholesterol level.Oligosaccharide has the physiologicals such as promotion Bifidobacterium thin
The effects such as bacterium propagation, optimization gut flora, correction intestinal bacilli illness, reduction blood sugar and prevention serum cholesterol are raised；Phosphatide
The reduction of HDL-C can be significantly inhibited.Therefore kelp dietary fiber, oligosaccharide, phosphatide are respectively provided with the effect of reduction blood fat, and effect
Mechanism is different, and this triple combination is applied the bright effect better than an independent composition of lipid-lowering effect by us.
Obesity, hypertension, high fat of blood and hyperglycaemia often nor individually occur, research find obesity, hypertension, height
Very close relation is there is between blood sugar and high fat of blood, patient is typically four kinds of symptoms to be occurred simultaneously；Constipation seems and " three
It is high " it doesn't matter, studies have found that, " three high " personage often has constipation situation, meanwhile, constipation often aggravates " three high " disease
The symptom of people.Treatment key currently for hypertension, high fat of blood, hyperglycaemia and constipation is still meals prevention, increasingly
Many scholars and scientist think to treat above-mentioned disease, are pursued in medicine and surgical breakthrough with it, can not show a candle to exist in early days
Prevention on meals, in fact once there is " three high " symptom, medicine can only be cured the symptoms, not the disease, and often for a certain
Individual symptom is treated, and can neither so reach comprehensive therapeutic effect, and huge side effect can be also brought on the contrary.Hypertension,
Relation and " three high " and the relation of constipation between hyperglycaemia and high fat of blood, often cause that problem becomes very complicated again.According to
The above-mentioned problem being previously mentioned, only single meals prevention can't probably reach the purpose of comprehensive improvement.Utilization of the invention
Tablet prepared by the allotment of kelp dietary fiber, oligosaccharide, phosphatide by carrying out science has, and eliminates constipation, reduces fat, drop
Low hypertension, reduction blood fat reduces the effect of blood sugar.So as to reach the purpose of complex treatment improvement.
Specific embodiment
To illustrate to realize technical scheme by embodiment below, these implementation methods are not intended to limit this
Invention.Those skilled in the art carry out equivalent or corresponding logic improvement to the present invention according to existing knowledge, belong to this hair
Bright scope.
The prescription of embodiment 1
| Embodiment 1 | Every consumption (g) | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.686 | 49.0 | 686.0 |
| Xylo-oligosaccharide | 0.35 | 25.0 | 350.0 |
| Phosphatide | 0.35 | 25.0 | 350.0 |
| Calcium stearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 200 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 14 mesh sieves, air blast is done in being put into 50 DEG C of -60 DEG C of baking ovens
Dry 1-2h；D) take out with 14 mesh sieve whole grains, add the lubricant (calcium stearate) of recipe quantity total mixed afterwards；E) compressing tablet：According to the rules
Piece weight piece.
The prescription of embodiment 2
| Embodiment 2 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Water-soluble kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.56 | 40.0 | 560.0 |
| Soybean lecithin | 0.4172 | 29.8 | 417.2 |
| Magnesium stearate | 0.0028 | 0.2 | 2.8 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 180 mesh sieves standby for water-soluble kelp dietary fiber；B) the water-soluble sea-tangle meals of recipe quantity are weighed
Food fiber, xylo-oligosaccharide, soybean lecithin close uniform；C) add the soft ability of Purified Water q. s system, pelletized with 16 mesh sieves, be put into 50 DEG C -60
Forced air drying 1-2h in DEG C baking oven；D) take out with 16 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total mixed afterwards；e)
Compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 3
Technical process：A) to cross 150 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Isomaltose, egg yolk lecithin are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 18 mesh sieves, be put into 50 DEG C of -60 DEG C of bakings
Forced air drying 1-2h in case；D) take out with 18 mesh sieve whole grains, add the lubricant (leucine) of recipe quantity total mixed afterwards；E) compressing tablet：
Piece weight piece according to the rules.
The prescription of embodiment 4
| Embodiment 4 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Water-insoluble kelp dietary fiber | 0.686 | 49.0 | 686.0 |
| Galactooligosaccharide | 0.56 | 40.0 | 560.0 |
| Lecithin | 0.14 | 10.0 | 140.0 |
| Odium stearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 120 mesh sieves standby for kelp dietary fiber；B) the water-insoluble sea-tangle meals for weighing recipe quantity are fine
Dimension, galactooligosaccharide, lecithin are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50 DEG C -60 DEG C
Forced air drying 1-2h in baking oven；D) take out with 20 mesh sieve whole grains, add the lubricant (odium stearate) of recipe quantity total mixed afterwards；E) press
Piece：Piece weight piece according to the rules.
The prescription of embodiment 5
| Embodiment 5 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Soyabean oligosaccharides | 0.406 | 29.0 | 406.0 |
| Phosphatide | 0.56 | 40.0 | 560.0 |
| Potassium stearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber, the soybean of recipe quantity are weighed
Oligosaccharide, phosphatide are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 30 mesh sieves, be put into air blast in 50 DEG C of -60 DEG C of baking ovens
Dry 1-2h；D) take out with 30 mesh sieve whole grains, add recipe quantity lubricant (potassium stearate) total mixed afterwards；E) compressing tablet：According to the rules
Piece weight piece.
The prescription of embodiment 6
| Embodiment 6 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Sodium alginate | 0.462 | 33.0 | 462.0 |
| Raffinose-oligosaccharide | 0.462 | 33.0 | 462.0 |
| Phosphatide | 0.462 | 33.0 | 462.0 |
| Magnesium stearate | 0.0084 | 0.6 | 8.4 |
| Silica | 0.0056 | 0.4 | 5.6 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross (sodium alginate) 80 mesh sieve standby for kelp dietary fiber；B) weigh recipe quantity sodium alginate,
Raffinose-oligosaccharide, phosphatide are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 30 mesh sieves, be put into 50 DEG C of -60 DEG C of baking ovens
Forced air drying 1-2h；D) take out with 30 mesh sieve whole grains, add the lubricant (magnesium stearate, silica) of recipe quantity total mixed afterwards；
E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 7
| Embodiment 7 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.3346 | 23.9 | 334.6 |
| Phosphatide | 0.56 | 40.0 | 560.0 |
| Aspartame | 0.0014 | 0.1 | 1.4 |
| Sodium chloride | 0.084 | 6.0 | 84.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 60 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric wood are weighed
Sugar, phosphatide, sweetener (aspartame) are well mixed；C) plus the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 40 DEG C-
Forced air drying 2-4h in 50 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (sodium chloride) of recipe quantity total mixed afterwards；e)
Compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 8
| Embodiment 8 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.98 | 70.0 | 980.0 |
| Trehalose | 0.2072 | 14.8 | 207.2 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Xylitol | 0.07 | 5.0 | 70.0 |
| Magnesium stearate | 0.0028 | 0.2 | 2.8 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber, the marine alga of recipe quantity are weighed
Sugar, phosphatide, sweetener (xylitol) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50 DEG C -60
Forced air drying 1-2h in DEG C baking oven；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total mixed afterwards；e)
Compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 9
| Embodiment 9 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.546 | 39.0 | 546.0 |
| Stachyose | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.42 | 30.0 | 420.0 |
| Sorbierite | 0.28 | 20.0 | 280.0 |
| Glycerin monostearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 120 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber, the wood of recipe quantity are weighed
Sugar, phosphatide, sweetener (sorbierite) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 60 DEG C -70
Forced air drying 0.5-1h in DEG C baking oven；D) take out with 20 mesh sieve whole grains, add the lubricant (glycerin monostearate) of recipe quantity
It is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 10
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Sugar,confectioner's, phosphatide, sweetener (sodium cyclamate is also known as honey element) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh sieves
Granulation, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (benzene of recipe quantity
Sodium formate) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 11
| Embodiment 11 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.693 | 49.5 | 693.0 |
| Arabinooligosaccharides | 0.343 | 24.5 | 343.0 |
| Phosphatide | 0.343 | 24.5 | 343.0 |
| Aspartame | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Arabinose, phosphatide, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out use 20 mesh sieve whole grains, addition recipe quantity lubricant (magnesium stearate) after
It is total mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 12
| Embodiment 12 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.7425 | 49.5 | 742.5 |
| Oligomeric coupling sugar | 0.3675 | 24.5 | 367.5 |
| Phosphatide | 0.3675 | 24.5 | 367.5 |
| Acesulfame potassium | 0.0075 | 0.5 | 7.5 |
| Silicified microcrystalline cellulose | 0.015 | 1.0 | 15.0 |
| It is total | 1.5 | 100.0 | 1500.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Coupling sugar, phosphatide, sweetener (acesulfame potassium) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (silicified microcrystalline cellulose of recipe quantity
Element) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 13
| Embodiment 13 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.495 | 49.5 | 495.0 |
| Oligomeric nigerose | 0.245 | 24.5 | 245.0 |
| Phosphatide | 0.245 | 24.5 | 245.0 |
| Neotame | 0.005 | 0.5 | 5.0 |
| Adipic acid | 0.01 | 1.0 | 10.0 |
| It is total | 1 | 100.0 | 1000.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Nigerose, phosphatide, sweetener (neotame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (adipic acid) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 14
| Embodiment 14 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.396 | 49.5 | 396.0 |
| Oligomeric isomaltulose | 0.196 | 24.5 | 196.0 |
| Phosphatide | 0.196 | 24.5 | 196.0 |
| Saccharin sodium | 0.004 | 0.5 | 4.0 |
| Fumaric acid | 0.008 | 1.0 | 8.0 |
| It is total | 0.8 | 100.0 | 800.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Isomaltulose, phosphatide, sweetener (saccharin sodium) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (fumaric acid) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 15
| Embodiment 15 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.3465 | 49.5 | 346.5 |
| Lactulose | 0.1715 | 24.5 | 171.5 |
| Phosphatide | 0.1715 | 24.5 | 171.5 |
| Alitame | 0.0035 | 0.5 | 3.5 |
| Palmitic acid | 0.007 | 1.0 | 7.0 |
| It is total | 0.7 | 100.0 | 700.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber, the breast fruit of recipe quantity are weighed
Sugar, phosphatide, sweetener (alitame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50 DEG C -60
Forced air drying 1-2h in DEG C baking oven；D) take out with 20 mesh sieve whole grains, add the lubricant (palmitic acid) of recipe quantity total mixed afterwards；E) press
Piece：Piece weight piece according to the rules.
The prescription of embodiment 16
| Embodiment 16 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.2475 | 49.5 | 247.5 |
| Oligomeric dragon gallbladder sugar | 0.1225 | 24.5 | 122.5 |
| Phosphatide | 0.1225 | 24.5 | 122.5 |
| Stevioside | 0.0025 | 0.5 | 2.5 |
| Magnesium stearate | 0.005 | 1.0 | 5.0 |
| It is total | 0.5 | 100.0 | 500.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Rough gentian sugar, phosphatide, sweetener (stevioside) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 17
| Embodiment 17 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.4032 | 28.8 | 403.2 |
| Phosphatide | 0.56 | 40.0 | 560.0 |
| Lactose | 0.014 | 1.0 | 14.0 |
| Macrogol 4000 | 0.0028 | 0.2 | 2.8 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, filler (lactose) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50 DEG C -60
Forced air drying 1-2h in DEG C baking oven；D) take out use 20 mesh sieve whole grains, add recipe quantity lubricant after (Macrogol 4000) always
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 18
| Embodiment 18 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Inulooligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Mannitol | 0.686 | 49.0 | 686.0 |
| Magnesium laurylsulfate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber, the inulin of recipe quantity are weighed
Oligosaccharide, phosphatide, filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium laurylsulfate) of recipe quantity
It is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 19
| Embodiment 19 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.98 | 70.0 | 980.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Microcrystalline cellulose | 0.056 | 4.0 | 56.0 |
| Talcum powder | 0.084 | 6.0 | 84.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, filler (microcrystalline cellulose) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (talcum powder) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 20
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, filler (soluble starch) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 21
| Embodiment 21 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.35 | 25.0 | 350.0 |
| Xylo-oligosaccharide | 0.343 | 24.5 | 343.0 |
| Phosphatide | 0.343 | 24.5 | 343.0 |
| Mannitol | 0.35 | 25.0 | 350.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, filler (mannitol) are well mixed；C) plus the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50 DEG C-
Forced air drying 1-2h in 60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total mixed afterwards；
E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 22
| Embodiment 22 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.6 | 30.0 | 600.0 |
| Xylo-oligosaccharide | 0.2 | 10.0 | 200.0 |
| Phosphatide | 0.2 | 10.0 | 200.0 |
| D-sorbite | 0.98 | 49.0 | 980.0 |
| Magnesium stearate | 0.02 | 1.0 | 20.0 |
| It is total | 2 | 100.0 | 2000.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, filler (D-sorbite) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into 50
Forced air drying 1-2h in DEG C -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant (magnesium stearate) of recipe quantity total afterwards
It is mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 23
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, soybean lecithin, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out use 20 mesh sieve whole grains, addition recipe quantity lubricant (magnesium stearate) after
It is total mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 24
| Embodiment 24 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.98 | 70.0 | 980.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Soybean lecithin | 0.2086 | 14.9 | 208.6 |
| Silica | 0.0014 | 0.1 | 1.4 |
| Magnesium stearate | 0.042 | 3.0 | 42.0 |
| Aspartame | 0.028 | 2.0 | 28.0 |
| It is total | 1.4 | 100.0 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, soybean lecithin, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add lubricant (magnesium stearate, two of recipe quantity
Silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 25
| Embodiment 25 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.84 | 60.0 | 840.0 |
| Xylo-oligosaccharide | 0.392 | 28.0 | 392.0 |
| Soybean lecithin | 0.14 | 10.0 | 140.0 |
| Silica | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| Aspartame | 0.007 | 0.5 | 7.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, soybean lecithin, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add lubricant (magnesium stearate, two of recipe quantity
Silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 26
| Embodiment 26 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.462 | 33.0 | 462.0 |
| Xylo-oligosaccharide | 0.35 | 25.0 | 350.0 |
| Soybean lecithin | 0.56 | 40.0 | 560.0 |
| Silica | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| Aspartame | 0.007 | 0.5 | 7.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, soybean lecithin, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add lubricant (magnesium stearate, two of recipe quantity
Silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 27
| Embodiment 27 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.6615 | 49.0 | 661.50 |
| Xylo-oligosaccharide | 0.33075 | 24.5 | 330.75 |
| Soybean lecithin | 0.33075 | 24.5 | 330.75 |
| Silica | 0.00675 | 0.5 | 6.75 |
| Magnesium stearate | 0.0135 | 1.0 | 13.50 |
| Aspartame | 0.00675 | 0.5 | 6.75 |
| It is total | 1.35 | 100 | 1350.00 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, soybean lecithin, sweetener (aspartame) are well mixed；C) add the soft ability of Purified Water q. s system, pelletized with 20 mesh sieves, be put into
Forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add lubricant (magnesium stearate, two of recipe quantity
Silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 28
| Embodiment 28 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.56 | 40.0 | 560.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Maltitol | 0.1946 | 13.9 | 194.6 |
| Macrogol 6000 | 0.084 | 6.0 | 84.0 |
| Aspartame | 0.0014 | 0.1 | 1.4 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (aspartame), filler (maltitol) are well mixed；C) the soft ability of Purified Water q. s system is added, with 20
Mesh sieve is pelletized, and is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubrication of recipe quantity
Agent (Macrogol 6000) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 29
| Embodiment 29 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.98 | 70.0 | 980.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Dextrin | 0.1302 | 9.3 | 130.2 |
| Magnesium stearate | 0.0028 | 0.2 | 2.8 |
| Aspartame | 0.007 | 0.5 | 7.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (aspartame), filler (dextrin) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh sieves
Granulation, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubrication of recipe quantity (stearic
Sour magnesium) always mix after agent；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 30
| Embodiment 30 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.56 | 40.0 | 560.0 |
| Starch | 0.014 | 1.0 | 14.0 |
| Stearic acid | 0.014 | 1.0 | 14.0 |
| Glucose | 0.252 | 18.0 | 252.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (glucose), filler (starch) are well mixed；C) the soft ability of Purified Water q. s system is added, with 20 mesh sieve series
Grain, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity (stearic
Acid) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 31
| Embodiment 31 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Reduced isomaltooligosaccharide | 0.686 | 49.0 | 686.0 |
| Magnesium stearate | 0.007 | 0.5 | 7.0 |
| Fructose | 0.007 | 0.5 | 7.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (fructose), filler (oligoisomaltose) are well mixed；C) the soft ability of Purified Water q. s system is added, with 20
Mesh sieve is pelletized, and is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubrication of recipe quantity
Agent (magnesium stearate) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 32
| Embodiment 32 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.462 | 33.0 | 462.0 |
| Xylo-oligosaccharide | 0.161 | 11.5 | 161.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Pregelatinized starch | 0.35 | 25.0 | 350.0 |
| Magnesium stearate | 0.007 | 0.5 | 7.0 |
| Xylitol | 0.28 | 20.0 | 280.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (xylitol), filler (pregelatinized starch) are well mixed；C) the soft ability of Purified Water q. s system is added, with 20
Mesh sieve is pelletized, and is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubrication of recipe quantity
Agent (magnesium stearate) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 33
| Embodiment 33 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.56 | 40.0 | 560.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Mannitol | 0.2352 | 16.8 | 235.2 |
| Silica | 0.0014 | 0.1 | 1.4 |
| Magnesium stearate | 0.042 | 3.0 | 42.0 |
| Xylitol | 0.0014 | 0.1 | 1.4 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (xylitol), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh sieves
Granulation, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity (hard
Fatty acid magnesium, silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 34
| Embodiment 34 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.98 | 70.0 | 980.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Mannitol | 0.014 | 1.0 | 14.0 |
| Silica | 0.042 | 3.0 | 42.0 |
| Magnesium stearate | 0.0014 | 0.1 | 1.4 |
| Xylitol | 0.0826 | 5.9 | 82.6 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (xylitol), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh sieves
Granulation, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity (hard
Fatty acid magnesium, silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 35
| Embodiment 35 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.56 | 40.0 | 560.0 |
| Starch | 0.07 | 5.0 | 70.0 |
| Silica | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| Xylitol | 0.189 | 13.5 | 189.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (xylitol), filler (starch) are well mixed；C) the soft ability of Purified Water q. s system is added, with 20 mesh sieve series
Grain, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, it is (hard after the lubricant of addition recipe quantity
Fatty acid magnesium, silica) it is total mixed；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 36
| Embodiment 36 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.483 | 34.5 | 483.0 |
| Xylo-oligosaccharide | 0.238 | 17.0 | 238.0 |
| Phosphatide | 0.238 | 17.0 | 238.0 |
| Mannitol | 0.14 | 10.0 | 140.0 |
| Silica | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| Maltose | 0.28 | 20.0 | 280.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (maltose), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh sieves
Granulation, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity (hard
Fatty acid magnesium, silica) it is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 37
| Embodiment 37 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.42 | 30.0 | 420.0 |
| Xylo-oligosaccharide | 0.14 | 10.0 | 140.0 |
| Phosphatide | 0.14 | 10.0 | 140.0 |
| Mannitol | 0.686 | 49.0 | 686.0 |
| Silica | 0.0028 | 0.2 | 2.8 |
| Magnesium stearate | 0.0084 | 0.6 | 8.4 |
| Sucralose | 0.0028 | 0.2 | 2.8 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (Sucralose), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh
Sieve series grain, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity
(magnesium stearate, silica) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 38
| Embodiment 38 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.63 | 45.0 | 630.0 |
| Xylo-oligosaccharide | 0.28 | 20.0 | 280.0 |
| Phosphatide | 0.28 | 20.0 | 280.0 |
| Mannitol | 0.182 | 13.0 | 182.0 |
| Silica | 0.007 | 0.5 | 7.0 |
| Magnesium stearate | 0.014 | 1.0 | 14.0 |
| Aspartame | 0.007 | 0.5 | 7.0 |
| It is total | 1.4 | 100 | 1400.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (aspartame), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh
Sieve series grain, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity
(magnesium stearate, silica) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
The prescription of embodiment 39
| Embodiment 39 | Every consumption g | Every consumption (%) | 1000 consumptions (g) |
| Kelp dietary fiber | 0.66 | 33.0 | 660.0 |
| Xylo-oligosaccharide | 0.33 | 16.5 | 330.0 |
| Phosphatide | 0.33 | 16.5 | 330.0 |
| Mannitol | 0.64 | 32.0 | 640.0 |
| Silica | 0.01 | 0.5 | 10.0 |
| Magnesium stearate | 0.02 | 1.0 | 20.0 |
| Aspartame | 0.01 | 0.5 | 10.0 |
| It is total | 2 | 100 | 2000.0 |
Technical process：A) to cross 100 mesh sieves standby for kelp dietary fiber；B) kelp dietary fiber of recipe quantity, oligomeric is weighed
Xylose, phosphatide, sweetener (aspartame), filler (mannitol) are well mixed；C) add the soft ability of Purified Water q. s system, use 20 mesh
Sieve series grain, is put into forced air drying 1-2h in 50 DEG C of -60 DEG C of baking ovens；D) take out with 20 mesh sieve whole grains, add the lubricant of recipe quantity
(magnesium stearate, silica) is total mixed afterwards；E) compressing tablet：Piece weight piece according to the rules.
Embodiment 40
With the tablet of embodiment 27, film-coating soluble in the stomach is wrapped, be made Film coated tablets.
Embodiment 41
With the tablet of embodiment 27, bag enteric film coat is made Film coated tablets.
Embodiment 42
With the tablet of embodiment 27, sugar coating is made sugar coated tablet.
Test example 1：Each made tablet basic parameter of embodiment
Appearance character：Using observation.
Weight differential：Enter according to the Pharmacopoeia of People's Republic of China lower weight differential method of version four 0101 tablets in 2015
Row is checked.
Hardness：Hardness is determined with Shanghai Huanghai Sea medicine inspection Instrument Ltd. YPD-200C matrix agent hardness-testing device.
Friability：Examined according to Pharmacopoeia of People's Republic of China four 0923 tablet friability inspection techniques of version in 2015
Look into.
Mouthfeel：Please 10 people tasted respectively, award scoring (0-10 point, worst 0 point of mouthfeel, best 10 points of mouthfeel) and taste
Gargled after finishing, taste the mouthfeel of next prescription after 30 minutes again.10 average values of people are taken for final mouthfeel index.Each reality
Apply the made tablet basic parameter measurement result of example and be shown in Table 1.
Test example 2：
840 constipation patients, are divided into 42 groups, every group 20, the tablet of each embodiment of this product, wherein embodiment are taken respectively
16 each serving 3, and embodiment 14,15,31,32,37 each takes 2, and, each serving 1,3 times a day for other each embodiments, even
Continuous medication 2 weeks, daily record times of defecation, defecation situation during medication.
Curative effect judging standard：1. it is effective：Clinical symptom disappearance, one time a day for stool, stabilization two weeks；2. it is effective：Clinical condition
Shape disappears or is clearly better substantially, and normal or number of times of defecating substantially increases；3. it is invalid：Symptom or times of defecation are without substantially changing
It is kind.Treatment constipation situation is shown in Table 2 after taking each embodiment product of this product.
Test example 3：
840 obese patients, are divided into 42 groups, every group 20, the tablet of each embodiment of this product, wherein embodiment are taken respectively
16 each serving 3, and embodiment 14,15,31,32,37 each takes 2, and, each serving 1,3 times a day for other each embodiments, even
Continuous medication 4 weeks, weighs with after treating 4 weeks before the treatment respectively, and statistical weight reduces more than 20kg, weight loss 10kg- respectively
20kg, body always reduces 5-12kg, and below weight loss 5kg number.Take body weight loss statistics after each implementation product
It is shown in Table 3.
Test example 4：
210 diabetics, are divided into 42 groups, every group 5, the tablet of each embodiment of this product are taken respectively, wherein implementing
Each serving 3, embodiment 14,15,31,32,37 each takes 2 to example 16, and, each serving 1,3 times a day for other each embodiments,
Continuous medication 3 months, carries out before medication and after taking medicine 3 months and glycosylated hemoglobin is determined respectively.Then 5 people's fasting bloods are taken
Sugar and glycosylated hemoglobin average value.
Take fasting blood-glucose and glycosylated hemoglobin mean variation situation before and after each embodiment product and be shown in Table 4.
Test example 5：
210 hyperlipemic patients, are divided into 42 groups, every group 5, the tablet of each embodiment of this product are taken respectively, wherein implementing
Each serving 3, embodiment 14,15,31,32,37 each takes 2 to example 16, and, each serving 1,3 times a day for other each embodiments,
Continuous medication 4 weeks, carries out lipid examination with after treating 4 weeks before the treatment respectively.Then the average value of 5 people's blood fat is taken.Take each
Embodiment product forward backward averaging Blood Lipid situation is shown in Table 5.
Test example 6：
840 hyperpietics, are divided into 42 groups, every group 20, the tablet of each embodiment of this product, wherein embodiment are taken respectively
16 each serving 3, and embodiment 14,15,31,32,37 each takes 2, and, each serving 1,3 times a day for other each embodiments, even
Continuous medication 4 weeks, measures blood pressure with after treating 4 weeks before the treatment respectively.Then the average value of 20 blood pressures is taken.Each embodiment is taken to produce
Product forward backward averaging blood pressure situation is shown in Table 6.
Test example 7:
In above-mentioned example 1-5, using visit at random and classified statistics by the way of inquired patient take after local flavor and
Mouthfeel, patient is indicated without bad flavor, it is easy to taken, good mouthfeel.
The made tablet basic parameter of each embodiment of table 1
| Appearance character | Tablet weight variation | Hardness kg (n=6) | Friability | Mouth feel score | |
| Embodiment 1 | Brown piece, smooth in appearance | Meet regulation | 5.28±0.64 | Without sliver and fragment 0.20 | 9.2 |
| Embodiment 2 | Brown piece, smooth in appearance | Meet regulation | 5.30±1.18 | Without sliver and fragment 0.01 | 9.2 |
| Embodiment 3 | Brown piece, smooth in appearance | Meet regulation | 4.59±0.67 | Without sliver and fragment 0.20 | 9.2 |
| Embodiment 4 | Brown piece, smooth in appearance | Meet regulation | 5.33±1.06 | Without sliver and fragment 0.18 | 8.4 |
| Embodiment 5 | Brown piece, smooth in appearance | Meet regulation | 4.88±0.58 | Without sliver and fragment 0.07 | 9.7 |
| Embodiment 6 | Brown piece, smooth in appearance | Meet regulation | 5.71±0.74 | Without sliver and fragment 0.19 | 9.8 |
| Embodiment 7 | Brown piece, smooth in appearance | Meet regulation | 4.75±0.52 | Without sliver and fragment 0.13 | 7.6 |
| Embodiment 8 | Brown piece, smooth in appearance | Meet regulation | 5.52±1.06 | Without sliver and fragment 0.01 | 7.5 |
| Embodiment 9 | Brown piece, smooth in appearance | Meet regulation | 5.38±0.68 | Without sliver and fragment 0.03 | 8.9 |
| Embodiment 10 | Brown piece, smooth in appearance | Meet regulation | 4.99±0.67 | Without sliver and fragment 0.04 | 7.0 |
| Embodiment 11 | Brown piece, smooth in appearance | Meet regulation | 4.51±0.86 | Without sliver and fragment 0.14 | 8.1 |
| Embodiment 12 | Brown piece, smooth in appearance | Meet regulation | 5.55±0.83 | Without sliver and fragment 0.01 | 9.2 |
| Embodiment 13 | Brown piece, smooth in appearance | Meet regulation | 5.72±0.53 | Without sliver and fragment 0.16 | 9.2 |
| Embodiment 14 | Brown piece, smooth in appearance | Meet regulation | 4.54±0.98 | Without sliver and fragment 0.15 | 7.1 |
| Embodiment 15 | Brown piece, smooth in appearance | Meet regulation | 4.07±0.67 | Without sliver and fragment 0.12 | 8.3 |
| Embodiment 16 | Brown piece, smooth in appearance | Meet regulation | 4.95±0.9 | Without sliver and fragment 0.04 | 8.1 |
| Embodiment 17 | Brown piece, smooth in appearance | Meet regulation | 4.63±0.61 | Without sliver and fragment 0.05 | 9.7 |
| Embodiment 18 | Brown piece, smooth in appearance | Meet regulation | 5.46±0.74 | Without sliver and fragment 0.02 | 8.2 |
| Embodiment 19 | Brown piece, smooth in appearance | Meet regulation | 4.74±0.94 | Without sliver and fragment 0.13 | 8.3 |
| Embodiment 20 | Brown piece, smooth in appearance | Meet regulation | 4.88±0.97 | Without sliver and fragment 0.08 | 9.1 |
| Embodiment 21 | Brown piece, smooth in appearance | Meet regulation | 5.35±1.26 | Without sliver and fragment 0.12 | 8.4 |
| Embodiment 22 | Brown piece, smooth in appearance | Meet regulation | 4.72±1.07 | Without sliver and fragment 0.13 | 7.8 |
| Embodiment 23 | Brown piece, smooth in appearance | Meet regulation | 4.01±0.75 | Without sliver and fragment 0.17 | 7.2 |
| Embodiment 24 | Brown piece, smooth in appearance | Meet regulation | 4.02±0.73 | Without sliver and fragment 0.19 | 9.0 |
| Embodiment 25 | Brown piece, smooth in appearance | Meet regulation | 5.03±1.09 | Without sliver and fragment 0.08 | 8.8 |
| Embodiment 26 | Brown piece, smooth in appearance | Meet regulation | 5.64±1.07 | Without sliver and fragment 0.03 | 9.9 |
| Embodiment 27 | Brown piece, smooth in appearance | Meet regulation | 5.61±0.54 | Without sliver and fragment 0.03 | 9.3 |
| Embodiment 28 | Brown piece, smooth in appearance | Meet regulation | 5.84±1.15 | Without sliver and fragment 0.03 | 8.2 |
| Embodiment 29 | Brown piece, smooth in appearance | Meet regulation | 5.01±1.13 | Without sliver and fragment 0.15 | 7.1 |
| Embodiment 30 | Brown piece, smooth in appearance | Meet regulation | 5.90±0.53 | Without sliver and fragment 0.18 | 7.6 |
| Embodiment 31 | Brown piece, smooth in appearance | Meet regulation | 4.59±0.52 | Without sliver and fragment 0.2 | 7.3 |
| Embodiment 32 | Brown piece, smooth in appearance | Meet regulation | 5.44±0.82 | Without sliver and fragment 0.16 | 7.7 |
| Embodiment 33 | Brown piece, smooth in appearance | Meet regulation | 5.93±1.06 | Without sliver and fragment 0.10 | 8.4 |
| Embodiment 34 | Brown piece, smooth in appearance | Meet regulation | 5.76±0.65 | Without sliver and fragment 0.18 | 9.7 |
| Embodiment 35 | Brown piece, smooth in appearance | Meet regulation | 4.15±0.83 | Without sliver and fragment 0.08 | 7.4 |
| Embodiment 36 | Brown piece, smooth in appearance | Meet regulation | 4.66±0.84 | Without sliver and fragment 0.10 | 7.5 |
| Embodiment 37 | Brown piece, smooth in appearance | Meet regulation | 5.27±0.52 | Without sliver and fragment 0.13 | 8.2 |
| Embodiment 38 | Brown piece, smooth in appearance | Meet regulation | 5.36±0.70 | Without sliver and fragment 0.10 | 9.0 |
| Embodiment 39 | Brown piece, smooth in appearance | Meet regulation | 5.69±1.07 | Without sliver and fragment 0.08 | 9.1 |
| Embodiment 40 | Film coated tablets | Meet regulation | 4.39±0.65 | / | 9.4 |
| Embodiment 41 | Film coated tablets | Meet regulation | 4.85±1.04 | / | 7.3 |
| Embodiment 42 | Sugar coated tablet | / | 5.34±1.10 | / | 7.8 |
Table 2 treats constipation situation after taking each embodiment product
| Effective (example) | Effectively (example) | Invalid (example) | Total (example) | |
| Embodiment 1 | 14 | 6 | 0 | 20 |
| Embodiment 2 | 12 | 7 | 1 | 20 |
| Embodiment 3 | 8 | 10 | 2 | 20 |
| Embodiment 4 | 11 | 8 | 1 | 20 |
| Embodiment 5 | 8 | 10 | 2 | 20 |
| Embodiment 6 | 9 | 9 | 2 | 20 |
| Embodiment 7 | 12 | 8 | 0 | 20 |
| Embodiment 8 | 10 | 9 | 1 | 20 |
| Embodiment 9 | 9 | 10 | 1 | 20 |
| Embodiment 10 | 10 | 10 | 0 | 20 |
| Embodiment 11 | 12 | 7 | 1 | 20 |
| Embodiment 12 | 11 | 9 | 0 | 20 |
| Embodiment 13 | 8 | 10 | 2 | 20 |
| Embodiment 14 | 10 | 9 | 1 | 20 |
| Embodiment 15 | 12 | 7 | 1 | 20 |
| Embodiment 16 | 11 | 8 | 1 | 20 |
| Embodiment 17 | 11 | 7 | 2 | 20 |
| Embodiment 18 | 11 | 8 | 1 | 20 |
| Embodiment 19 | 11 | 8 | 1 | 20 |
| Embodiment 20 | 11 | 8 | 1 | 20 |
| Embodiment 21 | 14 | 6 | 0 | 20 |
| Embodiment 22 | 11 | 7 | 2 | 20 |
| Embodiment 23 | 10 | 9 | 1 | 20 |
| Embodiment 24 | 11 | 8 | 1 | 20 |
| Embodiment 25 | 14 | 6 | 0 | 20 |
| Embodiment 26 | 14 | 6 | 0 | 20 |
| Embodiment 27 | 12 | 8 | 0 | 20 |
| Embodiment 28 | 13 | 6 | 1 | 20 |
| Embodiment 29 | 9 | 9 | 2 | 20 |
| Embodiment 30 | 11 | 8 | 1 | 20 |
| Embodiment 31 | 11 | 8 | 1 | 20 |
| Embodiment 32 | 13 | 7 | 0 | 20 |
| Embodiment 33 | 12 | 8 | 0 | 20 |
| Embodiment 34 | 12 | 7 | 1 | 20 |
| Embodiment 35 | 12 | 6 | 2 | 20 |
| Embodiment 36 | 10 | 8 | 2 | 20 |
| Embodiment 37 | 10 | 9 | 1 | 20 |
| Embodiment 38 | 12 | 6 | 2 | 20 |
| Embodiment 39 | 10 | 10 | 0 | 20 |
| Embodiment 40 | 9 | 9 | 2 | 20 |
| Embodiment 41 | 9 | 9 | 2 | 20 |
| Embodiment 42 | 12 | 7 | 1 | 20 |
Table 3 takes each implementation postpartum product body weight loss statistical form
Table 4 takes fasting blood-glucose and glycosylated hemoglobin mean variation situation before and after each embodiment product
Table 5 takes each embodiment product forward backward averaging Blood Lipid situation
Table 6 takes each embodiment product forward backward averaging blood pressure situation
Claims (23)
1. a kind of tablet containing kelp dietary fiber, it is characterised in that its active component is kelp dietary fiber, oligosaccharide, phosphorus
Fat, auxiliary material is pharmaceutically acceptable tablet preparation auxiliary material, and the auxiliary material comprises at least lubricant.
2. tablet according to claim 1, it is characterised in that in terms of mass fraction, the consumption of each composition is fine for sea-tangle meals
Tie up 30-70, oligosaccharide 10-40, phosphatidase 1 0-40, the lubricant 0.2-6 in auxiliary material.
3. tablet according to claim 1, it is characterised in that it is fine that the kelp dietary fiber is selected from water-soluble sea-tangle meals
One kind or its mixture in dimension, water-insoluble kelp dietary fiber.
4. tablet according to claim 3, it is characterised in that the water-soluble kelp dietary fiber is sodium alginate.
5. tablet according to claim 1, it is characterised in that the oligosaccharide be selected from xylo-oligosaccharide, oligoisomaltose,
FOS, galactooligosaccharide, soyabean oligosaccharides, raffinose-oligosaccharide, inulooligosaccharide, oligomeric dragon gallbladder sugar, oligomeric Ba Lajintang,
In oligomeric nigerose, oligomeric coupling sugar, arabinooligosaccharides, lactulose, trehalose, stachyose, shitosan, chitosan
One or more.
6. tablet according to claim 5, it is characterised in that the oligosaccharide is xylo-oligosaccharide.
7. tablet according to claim 1, it is characterised in that the phosphatide is selected from the phosphatide of plant origin, animal origin
One kind or its mixture in phosphatide, or plant origin phosphatide, the separated single component after purification of phosphatide of animal origin
Phosphatide；The phosphatide of wherein plant origin is derived from the phosphatide that soybean, cottonseed, rapeseed, shelled peanut, sunflower seeds etc. are made；Wherein
The phosphatide of animal origin refers to be organized as the phosphatide that raw material is made with the ovum of animal, brain, liver, kidney, heart, lung etc.；Wherein
Single component phosphatide after isolating and purifying is selected from lecithin, cephalin, lipositol, serinephosphatide, phosphatidyl glycerol, two phosphorus
Phosphatidyl glycerol, plasmalogen, lysophosphatide, sphingomyelins, glycosyl sphingolipid.
8. tablet according to claim 7, it is characterised in that the phosphatide of the plant origin is soybean lecithin, the animal
The phosphatide in source is egg yolk lecithin.
9. tablet according to claim 2, it is characterised in that the lubricant is selected from magnesium stearate, calcium stearate, tristearin
Sour zinc, stearic acid sodium, lithium stearate, potassium stearate, stearic acid, palmitic acid, magnesium trisilicate, synthetic wax, hard paraffin, hydrogenated vegetable
Oil, whale vinegar alcohol, glycerin monostearate, silicified microcrystalline cellulose, silica, talcum powder, Sodium Benzoate, enuatrol, bay
Alcohol sodium sulphate, magnesium laurylsulfate, adipic acid, fumaric acid, cetomacrogol 1000, Macrogol 4000, Macrogol 6000, chlorine
Change one or more in sodium, leucine.
10. tablet according to claim 9, it is characterised in that the lubricant is selected from magnesium stearate, silica or two
The mixture of person.
11. tablets according to claim 2, it is characterised in that the auxiliary material also contains sweetener, the sweetener is selected from
Aspartame, saccharin sodium, Sucralose, sodium cyclamate, alitame, neotame, acesulfame potassium, stevioside, mannitol, xylitol, mountain
One or more in pears alcohol, fructose, glucose, maltose, sucrose, the consumption number of sweetener is 0.1-20.
12. tablets according to claim 2, it is characterised in that the auxiliary material also contains filler, described filler choosing
From mannitol, lactose, microcrystalline cellulose, starch, pregelatinized starch, soluble starch, dextrin, D-sorbite, maltitol, low
One or more in IMO, the consumption number of filler is 1-49.
13. tablets according to claim 12, it is characterised in that described filler is mannitol.
14. tablets according to claim 1, it is characterised in that the Tabules is chewable tablets, used in chewable tablets
Kelp dietary fiber is the mixture of water-soluble kelp dietary fiber and water-insoluble kelp dietary fiber；Oligosaccharide used is low
Xylan；Phosphatide used is soybean lecithin；Auxiliary material used includes the lubricant that magnesium stearate and silica are constituted；Each composition
Consumption number is kelp dietary fiber 30-70, xylo-oligosaccharide 10-40, soybean lecithin 10-40, silica 0.1-3, stearic acid
Magnesium 0.1-3.
15. tablets according to claim 14, it is characterised in that also contain sweetener in auxiliary material, sweetener used is Ah Si
Pa Tan, consumption number is 0.1-2.
16. tablets according to claim 15, it is characterised in that kelp dietary fiber 49, xylo-oligosaccharide 24.5, soybean phosphorus
Fat 24.5, silica 0.5, magnesium stearate 1, aspartame 0.5.
17. tablets according to claim 1, it is characterised in that in the tablet, active component consumption number is sea-tangle
Dietary fiber 30-70, oligosaccharide 10-40, phosphatidase 1 0-40, the supplementary product consumption number is lubricant 0.2-6, sweetener 0.1-
20, filler 1-49.
18. tablets according to claim 17, it is characterised in that the lubricant is the mixed of magnesium stearate and silica
Compound, wherein magnesium stearate 0.1-3, silica 0.1-3.
19. tablet according to claim 1 to 18 any claim, it is characterized by being surrounded by film-coating or sugar outside tablet
Clothing.
The preparation method of 20. tablet according to any claim in claim 1 to 19, it is characterised in that including following
Step：
A), to cross 60-200 mesh sieves standby for kelp dietary fiber；
B) kelp dietary fiber, oligosaccharide, phosphatide, is weighed to be well mixed；
C), add water softwood processed, is pelletized with 14-30 mesh sieves, is put into forced air drying 0.5h-4h in 40 DEG C of -70 DEG C of baking ovens；
D), take out and use 14-30 mesh sieve whole grains, always mixed after adding lubricant；
E), piece weight piece according to the rules.
The preparation method of 21. tablets according to claim 20, it is characterised in that also include adding in step b) lubricating
The step of other auxiliary materials outside agent.
The preparation method of 22. tablets according to claim 20, it is characterised in that also thin comprising bag is carried out to gained tablet
The step of film clothing or sugar-coat.
23. tablet according to any claim in claim 1 to 19 is preparing treatment constipation, obesity, diabetes, height
Application in terms of blood fat or hypertension drug or health food.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611021537.1A CN106723087A (en) | 2016-11-21 | 2016-11-21 | A kind of tablet containing kelp dietary fiber and preparation method thereof |
| CN202111337019.1A CN114052261A (en) | 2016-11-21 | 2016-11-21 | Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611021537.1A CN106723087A (en) | 2016-11-21 | 2016-11-21 | A kind of tablet containing kelp dietary fiber and preparation method thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111337019.1A Division CN114052261A (en) | 2016-11-21 | 2016-11-21 | Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106723087A true CN106723087A (en) | 2017-05-31 |
Family
ID=58968268
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611021537.1A Pending CN106723087A (en) | 2016-11-21 | 2016-11-21 | A kind of tablet containing kelp dietary fiber and preparation method thereof |
| CN202111337019.1A Pending CN114052261A (en) | 2016-11-21 | 2016-11-21 | Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111337019.1A Pending CN114052261A (en) | 2016-11-21 | 2016-11-21 | Application of phospholipid in reducing friability of kelp dietary fiber chips and improving taste |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN106723087A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107136280A (en) * | 2017-06-05 | 2017-09-08 | 清华大学 | A kind of high content laminarin pressed candy and preparation method thereof |
| CN107183727A (en) * | 2017-06-01 | 2017-09-22 | 四川惠泰农业科技有限公司 | A kind of beta glucan drink for improving alimentary canal microecosystem and preparation method thereof |
| CN107467654A (en) * | 2017-07-17 | 2017-12-15 | 当代海洋生物科技（深圳）有限公司 | One main laminaria sea cucumber composite extract and its preparation method and application |
| CN107496903A (en) * | 2017-08-25 | 2017-12-22 | 王海军 | A kind of melbine and preparation method thereof |
| CN107853713A (en) * | 2017-11-22 | 2018-03-30 | 武汉轻工大学 | It is a kind of beneficial to composite dietary fiber of intestinal health and preparation method thereof |
| CN108464507A (en) * | 2018-03-29 | 2018-08-31 | 郑州四维健康管理有限公司 | A kind of instant capacity phospholipid powder, relax bowel product and preparation method thereof |
| CN108720029A (en) * | 2018-04-27 | 2018-11-02 | 吉林省倍减生物科技有限公司 | A kind of meal fiber tablet and preparation method thereof with antiobesity action |
| CN108813444A (en) * | 2018-06-05 | 2018-11-16 | 青岛明月海藻生物科技有限公司 | A kind of seaweed diet fiber freezes and preparation method thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101317666A (en) * | 2008-07-18 | 2008-12-10 | 罗文礼 | High-efficiency composite food cellulose and preparation method thereof |
| CN101589799A (en) * | 2008-05-29 | 2009-12-02 | 黄锦周 | A kind of multi-nutrient breakfast |
| CN102077936A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special sea dietary food for diabetics |
| CN102687750A (en) * | 2012-06-13 | 2012-09-26 | 杭州诺伽特健康科技有限公司 | Weight losing and meal replacement protein type solid beverage |
| CN103202469A (en) * | 2013-03-28 | 2013-07-17 | 吉林大学 | Egg yolk lecithin microcapsules and preparation method thereof |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105249480A (en) * | 2015-10-27 | 2016-01-20 | 新疆于田瑰觅生物科技股份有限公司 | Chewable tablet with dietary fiber and bifidobacteria and preparing method thereof |
| CN105941786A (en) * | 2016-04-28 | 2016-09-21 | 膳立方生物科技（上海）有限公司 | Sweets rich in dietary fibers and preparation method of sweets |
-
2016
- 2016-11-21 CN CN201611021537.1A patent/CN106723087A/en active Pending
- 2016-11-21 CN CN202111337019.1A patent/CN114052261A/en active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101589799A (en) * | 2008-05-29 | 2009-12-02 | 黄锦周 | A kind of multi-nutrient breakfast |
| CN101317666A (en) * | 2008-07-18 | 2008-12-10 | 罗文礼 | High-efficiency composite food cellulose and preparation method thereof |
| CN102077936A (en) * | 2010-09-20 | 2011-06-01 | 王强 | Special sea dietary food for diabetics |
| CN102687750A (en) * | 2012-06-13 | 2012-09-26 | 杭州诺伽特健康科技有限公司 | Weight losing and meal replacement protein type solid beverage |
| CN103202469A (en) * | 2013-03-28 | 2013-07-17 | 吉林大学 | Egg yolk lecithin microcapsules and preparation method thereof |
Non-Patent Citations (4)
| Title |
|---|
| 吕钟钟: "海藻复合膳食纤维的制备及其生物活性研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 奚念朱等: "《药剂学》", 30 April 1996, 人民卫生出版社 * |
| 汪勇等: "《粮油副产物加工技术》", 31 July 2016, 暨南大学出版社 * |
| 詹益兴等: "《绿色精细化工-天然产品制造法》", 31 January 2008, 科学技术出版社 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107183727A (en) * | 2017-06-01 | 2017-09-22 | 四川惠泰农业科技有限公司 | A kind of beta glucan drink for improving alimentary canal microecosystem and preparation method thereof |
| CN107136280A (en) * | 2017-06-05 | 2017-09-08 | 清华大学 | A kind of high content laminarin pressed candy and preparation method thereof |
| CN107467654A (en) * | 2017-07-17 | 2017-12-15 | 当代海洋生物科技（深圳）有限公司 | One main laminaria sea cucumber composite extract and its preparation method and application |
| CN107496903A (en) * | 2017-08-25 | 2017-12-22 | 王海军 | A kind of melbine and preparation method thereof |
| CN107853713A (en) * | 2017-11-22 | 2018-03-30 | 武汉轻工大学 | It is a kind of beneficial to composite dietary fiber of intestinal health and preparation method thereof |
| CN108464507A (en) * | 2018-03-29 | 2018-08-31 | 郑州四维健康管理有限公司 | A kind of instant capacity phospholipid powder, relax bowel product and preparation method thereof |
| CN108720029A (en) * | 2018-04-27 | 2018-11-02 | 吉林省倍减生物科技有限公司 | A kind of meal fiber tablet and preparation method thereof with antiobesity action |
| CN108813444A (en) * | 2018-06-05 | 2018-11-16 | 青岛明月海藻生物科技有限公司 | A kind of seaweed diet fiber freezes and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114052261A (en) | 2022-02-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106723087A (en) | A kind of tablet containing kelp dietary fiber and preparation method thereof | |
| CA2473209C (en) | Stimulation of the immune system with polydextrose | |
| CN106690331A (en) | Kelp dietary fiber granules and preparation method thereof | |
| CN106954847A (en) | Ferment probiotic composition with function of relaxing bowel, using and process preparation | |
| CN104643250B (en) | It is a kind of can bidirectional modulation body weight improve inferior health solid beverage | |
| CN102273585B (en) | Health-care porridge with effect of relaxing bowel and preparation method thereof | |
| CN107319525A (en) | One kind fat-reducing fat reducing tailored version clinical nutrition formula and preparation method thereof | |
| ES2682940T3 (en) | Composition comprising ocra for use in reducing the absorption of food fat | |
| CN104366480A (en) | Lipid-lowering and weight-reducing nutritional meal powder and preparation method thereof | |
| JP2002508772A (en) | Health supplement | |
| CN106722206A (en) | A kind of composition for alleviating alimentary canal malaise symptoms and/or emotional stress and products thereof | |
| CN107467462A (en) | A kind of generation meal solid beverage for contributing to fat-reducing and preparation method thereof | |
| WO2011060585A1 (en) | Chewable tablets including essences of five-colour fruits and vegetables and preparative methods thereof | |
| CN108685100A (en) | A kind of compound small peptide powder formula and preparation method thereof | |
| CN112369606A (en) | Low-carbon ketogenic food and preparation method thereof | |
| NO320546B1 (en) | Prebiotic combination products | |
| CA2983823A1 (en) | Plant extracts for the treatment of excess weight and obesity | |
| CN111543605A (en) | Comprehensive nutrition powder for people with hypertension, hyperlipidemia and obesity | |
| CN114376235A (en) | Weight-reducing probiotics and prebiotics composition beneficial to controlling in vivo fat and preparation method thereof | |
| CN112167639A (en) | Composition for bidirectionally regulating morning-onset intestinal fluid balance, preparation method and application thereof | |
| Tabrizi et al. | Functional laxative foods: Concepts, trends and health benefits | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| CN107259363A (en) | Diabetes patient's five cereals meal replacement powder | |
| WO2005056022A1 (en) | Enteropathy ameliorating composition | |
| US6506420B2 (en) | Combinations of psyllium and chitosan for synergistic adsorption of triglyceride |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: Room 1203, building D, No. 606, ningliu Road, Changlu street, Jiangbei new district, Nanjing City, Jiangsu Province Applicant after: Nanjing century Bokang Pharmaceutical Technology Co.,Ltd. Address before: 100070 Beijing City, Fengtai District Fengtai Science City Haiying Road No. 9 Jintang Building 2 701 Applicant before: BEIJING CENTURY BIOCOM PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170531 |
|
| RJ01 | Rejection of invention patent application after publication |